Jeffrey McKenna

Title: Jeffrey McKenna: Innovator in Targeted Protein Degradation

Introduction

Jeffrey McKenna is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of targeted protein degradation, particularly through his innovative patent. His work focuses on the development of compositions and methods for targeting E3 ligases, which play a crucial role in cellular processes.

Latest Patents

McKenna holds a patent titled "Covalent targeting of E3 ligases." This patent discloses compositions and methods for targeting E3 ligases. It includes a targeted protein degrader that consists of a targeted protein binder and an E3 Ubiquitin ligase binder. Notably, the E3 Ubiquitin ligase mentioned in the patent is human RNF4 or human RNF114. Additionally, the patent provides a pharmaceutical composition that includes a compound described within, along with a pharmaceutically acceptable excipient. He has 1 patent to his name.

Career Highlights

Throughout his career, McKenna has worked with prominent organizations, including Novartis AG and the University of California. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of McKenna's notable coworkers include Carl C. Ward and Thomas John Maimone. Their collaborative efforts have further advanced the research and development of targeted protein degradation technologies.

Conclusion

Jeffrey McKenna's innovative work in the field of targeted protein degradation has the potential to impact therapeutic strategies significantly. His contributions, particularly through his patent on E3 ligase targeting, highlight the importance of innovation in addressing complex biological challenges.